Despite the advances in CF therapies, the TEZA-IVA combination demonstrated only modest therapeutic effects in PwCF homozygous for F508del-CFTR (similar to LUMA-IVA combination [14,15]) or heterozygous with a second mutation resulting from CFTR residual function [16]. Here, CFTR is linked to cystic fibrosis.